Ezetimibe: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>David E. Volk
No edit summary
imported>David E. Volk
m (Registered Trade mark)
Line 2: Line 2:
[[Image:Ezetimibe structure.jpg|right|thumb|200px|{{#ifexist:Template:Ezetimibe structure.jpg/credit|{{Ezetimibe structure.jpg/credit}}<br/>|}}Ezetimibe.]]  
[[Image:Ezetimibe structure.jpg|right|thumb|200px|{{#ifexist:Template:Ezetimibe structure.jpg/credit|{{Ezetimibe structure.jpg/credit}}<br/>|}}Ezetimibe.]]  


'''Ezetimibe''', sold under the brand names '''Ezedoc''', '''Zetia''' and '''Ezetrol''', is an anti-[[hyperlipidemic]] medication used to lower [[cholesterol]] levels.  It appears to bind to a critical mediator of cholesterol absorption, the Niemann-Pick C1-Like 1 (NPC1L1) protein on the gastrointestinal tract epithelial cells as well as in [[hepatocyte]]s.  This mechanism differs from those of other classes of cholesterol-reducing compounds (HMG-CoA reductase inhibitors, bile acid sequestrants, fibric acid derivatives, and plant stanols). Ezetimibe does not inhibit cholesterol synthesis in the liver, or increase bile acid excretion but instead localizes and appears to act at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood; this distinct mechanism is complementary to that of [[HMG-CoA reductase inhibitor]]s.
'''Ezetimibe''', sold under the brand names '''Ezedoc'''®, '''Zetia'''® and '''Ezetrol'''®, is an anti-[[hyperlipidemic]] medication used to lower [[cholesterol]] levels.  It appears to bind to a critical mediator of cholesterol absorption, the Niemann-Pick C1-Like 1 (NPC1L1) protein on the gastrointestinal tract epithelial cells as well as in [[hepatocyte]]s.  This mechanism differs from those of other classes of cholesterol-reducing compounds (HMG-CoA reductase inhibitors, bile acid sequestrants, fibric acid derivatives, and plant stanols). Ezetimibe does not inhibit cholesterol synthesis in the liver, or increase bile acid excretion but instead localizes and appears to act at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood; this distinct mechanism is complementary to that of [[HMG-CoA reductase inhibitor]]s.





Revision as of 16:34, 28 January 2008

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.
(CC) Image: David E. Volk
Ezetimibe.

Ezetimibe, sold under the brand names Ezedoc®, Zetia® and Ezetrol®, is an anti-hyperlipidemic medication used to lower cholesterol levels. It appears to bind to a critical mediator of cholesterol absorption, the Niemann-Pick C1-Like 1 (NPC1L1) protein on the gastrointestinal tract epithelial cells as well as in hepatocytes. This mechanism differs from those of other classes of cholesterol-reducing compounds (HMG-CoA reductase inhibitors, bile acid sequestrants, fibric acid derivatives, and plant stanols). Ezetimibe does not inhibit cholesterol synthesis in the liver, or increase bile acid excretion but instead localizes and appears to act at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood; this distinct mechanism is complementary to that of HMG-CoA reductase inhibitors.


Its chemical IUPAC name is (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl) azetidin-2-one and its chemical formula is C24H21F2NO3.

Drug interactions

Cholestyramine decreases the levels of ezetimibe while cyclosporine increases the effect and toxicity of ezetimibe. Ezetimibe can be taken without regard to food.

External Links